Navigation Links
FDA Gives Clinical Trial Green Light on Drug to Treat Alzheimer's Disease
Date:4/22/2009

Previous Studies Show Bryostatin Protects Against Alzheimer's Protein, Rewires and Repairs Brain Damage

MORGANTOWN, W.Va., April 22 /PRNewswire-USNewswire/ -- The Food and Drug Administration (FDA) has given the Blanchette Rockefeller Neurosciences Institute (BRNI) the go-ahead to conduct Phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease patients. The drug showed pre-clinical efficacy to not only treat Alzheimer's disease symptoms, but also its underlying causes.

"We are very excited about the FDA's agreement for BRNI to move forward with clinical trials," said Dr. Daniel Alkon, Scientific Director of BRNI. "Bryostatin shows the promise to repair and protect against neurodegeneration caused by Alzheimer's disease, stroke and other brain trauma, as well as enhance the brain's normal memory functions."

Bryostatin was originally created as an anti-cancer chemotherapy. When BRNI scientists extensively tested PKC activators against Alzheimer's disease models, they discovered the drug's hidden potential to stop Alzheimer's disease. Over the past six years, the drug has shown remarkable possibilities. In preclinical testing, BRNI scientists experimented with Bryostatin on three species of Alzheimer's disease transgenic mice, each species based on different human Alzheimer's disease genes. The test results revealed that Bryostatin, and a related class of drugs discovered at BRNI, can reduce the toxic Alzheimer's disease protein A Beta, restore lost synapses, and protect against the loss of memory functions. In related preclinical testing, Bryostatin has been shown to enhance and restore memory by rewiring connections in the brain previously destroyed by stroke, head trauma, or aging itself.

The Phase II trials, slated to begin in approximately two to four months, will test these preclinical findings on human Alzheimer's disease patients as well as controls, along with Bryostation's effects on molecular targets in the human body, such as the signaling enzyme PKC. The drug's side effects will also be carefully monitored using low doses that were previously found to be generally benign in human cancer patients.

"With the potential to not just treat symptoms, but also stop the causes, the Bryostatin trial on Alzheimer's disease patients represents a new direction for the treatment of a disease with no current cure," said Alkon. "And the timing is crucial because as many as 5.3 million people live with Alzheimer's disease in the United States alone, with a new American developing Alzheimer's disease every 70 seconds."

About BRNI

BRNI is the world's only non-profit institute dedicated to the study of both human memory and diseases of memory. Its primary mission is to accelerate the transfer of neurological discoveries from the lab to the doctor's office where it can benefit patients who suffer from neurological and psychiatric diseases.

BRNI is operated in alliance with West Virginia University in Morgantown as well as in collaboration with other academic institutions such as Johns Hopkins University. West Virginia Senator Jay Rockefeller founded the Institute in memory of his mother, Blanchette Hooker Rockefeller, who died of Alzheimer's disease.


'/>"/>
SOURCE Blanchette Rockefeller Neurosciences Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Health Care Policy Analyst Gives SALGBA Attendees a Glimpse of the Future
2. ScheduleAnywhere.com Gives Managers New Tools to Create Employee Schedules and Reduce Overtime
3. Nevada Breast Augmentation Surgeon Gives Reno Patients a Glimpse of Likely Results with Portrait 3D Computer Imagery
4. The Marcus Foundation Gives $20 Million to Grady Health System
5. New Program Gives Guardian Dental Pre-Paid/DHMO Members Greater Access to Specialty Care
6. Entertainment Fusion Group Gives Back
7. Rhode Island Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Highest Cigarette Tax in the Nation
8. American Heart Association Statement Gives Guidance on Minimally Invasive Procedures to Treat Diseased Brain Vessels
9. NASDAQ Gives Dynatronics a Third Three-Month Extension for Minimum Bid Price Compliance
10. New Mobile Patient Communicator(TM) Gives Patients an Interactive Education Tool and Boosts Nurse Productivity
11. Singapore Gives New Sight to the Blind
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 26, 2016 One of Australia,s ... formation of a new biotechnology company, Noxopharm Limited [ABN 50 608 ... IPO and to list on the ASX. Noxopharm is ... to enter a Phase 1 clinical study later this year. ... one of the biggest problems facing cancer patients - the ability ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: